RxDoctor Payments Data

Ratnavali Kolla, MD

Neurology · Silver Spring, MDNPI 1174617625

Payments from drug & device makers

$15,288in general payments, 2019–2025

Across 957 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AbbVie$2K
  • Biogen$1K
  • Lilly USA, LLC$1K
  • Neurelis, Inc.$651
  • UCB, Inc.$638
  • plus $8K from 46 others

What the payments were for

  • Speaking & faculty fees$280%
  • Food & beverage$15,221100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,288 in reported general payments places this provider in the 70th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$264,684
Medicare patients
680
Services billed
2,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate22$207,110
AubagioTeriflunomide14$122,466
Kesimpta PenOfatumumab14$111,745
AptiomEslicarbazepine Acetate38$86,190
BriviactBrivaracetam32$83,214
CopaxoneGlatiramer Acetate13$75,281
Teriflunomide15$66,975
RytaryCarbidopa/Levodopa42$36,353
Emgality PenGalcanezumab-Gnlm47$31,553
Nurtec OdtRimegepant Sulfate32$31,094
Gabapentin737$11,822
UbrelvyUbrogepant11$11,530
Rivastigmine33$9,295
Oxcarbazepine113$7,040
Topiramate ErTopiramate18$6,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,200$207,11022 claims
SanofiAubagio$275$122,46614 claims
UCB, Inc.Briviact$638$83,21432 claims
Teva Pharmaceuticals USA, Inc.Copaxone$496$75,28113 claims
Amneal Pharmaceuticals LLCRytary$161$36,35342 claims
PfizerNurtec Odt$181$31,09432 claims
AbbVieUbrelvy$1,530$11,53011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 442 neurology providers in Maryland.

Other neurology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →